Key Updates in Non-Metastatic and Metastatic Prostate Cancer Treatment

Expert panelists review new data on treatment and management of nmCRPC, mHSPC, and mCRPC and consider how these data may impact clinical practice.

EP. 21: Practical Application of PARP Inhibitors in Metastatic CRPC

May 24th 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

EP. 22: IO Therapy in mCRPC and Clinical Pearls

May 24th 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.